Eliem Therapeutics (ELYM)
(Delayed Data from NSDQ)
$8.65 USD
-0.25 (-2.81%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $8.64 -0.01 (-0.12%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ELYM 8.65 -0.25(-2.81%)
Will ELYM be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ELYM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ELYM
Eliem (ELYM) to Explore Strategic Options, Stock Rises 6%
ELYM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for ELYM
Insider Sale at Eliem Therapeutics Inc: EVP, R&D AND CSO Valerie Morisset Sells Shares
IQVIA Posts Upbeat Earnings, Joins Terex, Reddit And Other Big Stocks Moving Higher On Monday
Insider Sale at Eliem Therapeutics Inc (ELYM): EVP, R&D AND CSO Valerie Morisset Sells ...
EVP, R&D AND CSO Valerie Morisset Sells 50,000 Shares of Eliem Therapeutics Inc (ELYM)
Insider Sale at Eliem Therapeutics Inc (ELYM): EVP, R&D AND CSO Valerie Morisset Sells ...